BridgeBio Pharma IPO

6/26/2019

IPO

$348,500,000

Per the firm's latest filing, it plans to use the net proceeds from the IPO as follows: approximately $190.0 million to $210.0 million to fund the continued development, pre-commercialization, and potential commercialization costs of our key value drivers, BBP-831, BBP-454 and BBP-631, including: with respect to BBP-831, the completion of our Phase 2 clinical trial and potential NDA submission as a treatment for CCA in the second-line or later setting, as well as the advancement of our planned clinical trials in achondroplasia, first-line CCA, adjuvant UC, and tumors with FGFR fusions; with respect to BBP-454, the anticipated nomination of a development candidate and initiation of IND-enabling studies; and with respect to BBP-631, the anticipated filing of an IND and initiation of a first-in-human clinical trial; approximately $45.0 million to $55.0 million to fund the continued development, pre-commercialization, and potential commercialization costs of our development programs that a

Publicly-held

Biopharmaceutical

421 Kipling St.
Palo Alto, CA 94301
USA

BridgeBio Pharma (Nasdaq: BBIO) is a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.